Genedrive launches £5.5m fundraise to drive pharmacogenetic growth

Genedrive ( (GB:GDR) ) has shared an announcement.

Genedrive plc plans to raise up to £5.5 million through a combination of a direct subscription, a conditional placing and an open offer to existing shareholders, all priced at 1.0 pence per new share, a 7.4% discount to the latest closing price. The largest and a significant shareholder will subscribe for up to £3.5 million, while the CEO and CFO intend to participate via the open offer, and a £500,000 shareholder loan will be converted to equity upon completion, releasing a debenture over the company’s assets.

The funds will be used to accelerate commercial rollout and market expansion in the UK, Europe and the Middle East, support an FDA 510(k) submission for its CYP2C19 test around June 2026, scale manufacturing, improve product usability and extend its IP into a laboratory-based CYP2C19 assay. Management warns that if only the firm subscription completes, cash runway extends only into March 2026, underscoring the importance of shareholder approval and full take-up of the conditional elements of the fundraising for the company’s going-concern position and growth plans.

The most recent analyst rating on (GB:GDR) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.

Spark’s Take on GB:GDR Stock

According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.

The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).

To see Spark’s full report on GB:GDR stock, click here.

More about Genedrive

Genedrive plc is a Manchester-based diagnostics company specialising in point-of-care pharmacogenetic testing, notably its CYP2C19 genotyping assays. The group focuses on rapid, decentralised genetic tests for personalised medicine, targeting healthcare markets in the UK, Europe and the Middle East, with plans to expand into both point-of-care and laboratory platforms.

Average Trading Volume: 8,782,537

Technical Sentiment Signal: Sell

Current Market Cap: £11.33M

Learn more about GDR stock on TipRanks’ Stock Analysis page.